The international project CLUB120 offers innovative products based on short peptides known worldwide as KHAVINSON PEPTIDES®. 

KHAVINSON PEPTIDES® were first developed in the 70s of the 20th century by a group of scientists led by Professor Vladimir Khavinson. In 40 years of scientific and clinical research, the high efficiency of short peptides in restoring the structure and function of affected cells has been proven.

In the course of experiments, scientists have found that peptides can increase the vital reserve of the cell and stimulate protein biosynthesis. It was also revealed that peptides' specific binding to single-stranded DNA regions can positively influence gene expression.

These discoveries became the basis for the development of drugs with the addition of short peptides.

Since 1973, Professor Khavinson and his team have extracted about 40 complexes of physiologically active peptides, which have received patents in the USA, Canada, Australia, Europe, Japan, Korea, Israel and other countries.

Many of the developed peptides were included in the composition of well-known drugs used in neurology, endocrinology, ophthalmology, cardiology, therapy, reproductive medicine, etc.

Biotechnology, created by Professor Khavinson, is currently applied not only in general but also in space medicine, as well as in the industrial and military sectors. In addition, preparations based on short peptides were used to treat people affected by cataclysms, accidents on nuclear submarines, and the Chernobyl nuclear power plant.

Long-term human studies have demonstrated the ability of KHAVINSON PEPTIDES® to increase the vital resource of the body and significantly reduce mortality among elderly patients.

You can get acquainted with the numerous publications here.